Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Lumexa Imaging Holdings, Inc. ( (LMRI) ).
Lumexa Imaging reported preliminary, unaudited results for the fourth quarter and full year ended Dec. 31, 2025, showing solid top-line growth and improving profitability despite ongoing net losses. Fourth-quarter consolidated revenue rose 7.9% year on year to $267.7 million, with system-wide revenue up 10.6%, same-center advanced volume growth of 12.7% consolidated and 9.2% system-wide, and adjusted EBITDA up 18.6% to $63.8 million, while the net loss widened modestly to $28.7 million.
For 2025 as a whole, consolidated revenue increased 7.8% to $1.023 billion, system-wide revenue grew 8.2%, and adjusted EBITDA climbed 14.6% to $230.2 million with margins above 22%, as the company added ten new imaging facilities and cut its net loss to $47.1 million from $94.1 million. Management highlighted a two-turn reduction in leverage from 5.5x to 3.5x, producing more than $50 million in annual cash savings, and reaffirmed 2026 guidance for modest revenue and adjusted EBITDA growth plus new adjusted EPS targets, signaling confidence in continued volume gains and margin expansion as outpatient advanced imaging volumes rise and new centers ramp.
The most recent analyst rating on (LMRI) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Lumexa Imaging Holdings, Inc. stock, see the LMRI Stock Forecast page.
More about Lumexa Imaging Holdings, Inc.
Lumexa Imaging Holdings, Inc., which operates as Lumexa Imaging (Nasdaq: LMRI), is one of the largest U.S. providers of outpatient imaging services. The company focuses on advanced imaging modalities such as MRI and CT, expanding through de novo centers, joint ventures and acquisitions to capture growing demand for lower-cost, non-hospital imaging.
Its market strategy emphasizes same-center growth, geographic expansion and a higher mix of advanced procedures, aiming to leverage the broader shift of imaging volumes from inpatient to outpatient settings. By strengthening its balance sheet and scaling its network, Lumexa seeks to enhance margins while improving access for patients, providers and payors across its system-wide footprint.
Average Trading Volume: 757,180
Current Market Cap: $1.05B
For detailed information about LMRI stock, go to TipRanks’ Stock Analysis page.